Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies





Published: November 2013 | Pages: 80 | Format: PDF

 Summary 

 GBI Research has released its pharma research, Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies, which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications. 

 Scope 

 

  •  Disease overview and treatment usage patterns 
  •  Market size and forecast for glaucoma and DES in Top Eight Markets (the US, the UK, France, Germany, Italy, Spain, Japan and Canada) from 2012 to 2019 
  •  Major marketed products for the indications types covered 
  •  In-depth pipeline analysis for glaucoma and DES 
  •  Key drivers and restraints that have had and are expected to have a significant impact upon the market 
  •  Key licensing and co-development agreements in the ophthalmology market 

 

 Reasons to buy 

 The report will enhance your decision-making capability by allowing you to - 

 

  •  Align your product portfolio to the markets with high growth potential 
  •  Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth 
  •  Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market 
  •  Develop key strategic initiatives based upon an understanding of key focus areas and leading companies 
  •  Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships 

 

 Additional Information 

 Ophthalmology Therapeutics in Major Markets is Expected to Reach $6.1 Billion by 2019, with Growth of 7.6% 

 The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in the Major Markets for the sector, the US, the UK, France, Germany, Italy, Spain, Canada Japan, was worth $3.7 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to reach $6.1 billion by 2019. 

 The top five European markets (the UK, France, Germany, Italy and Spain) are expected to show the fastest growth over the forecast period, with a CAGR of 20.4%. The other three markets are expected to see similar but slightly lower CAGRs, with Canada at 9.8%, the US at 4.3%, and Japan at 2.7%. The US had the largest market in 2012, with a value of $1.9 billion, or 52% of the total ophthalmology market. The next-largest market was Japan with $1,065m or 29% of the total Major Markets. In the same year, the top five European markets were valued at $549m, a share of 15%. Canada had the lowest market share at 4%, with a market value of $144m. 

 Moderate Pipeline with Promising Drugs in Late Stages of Development could Drive Market Expectations 

 The global ophthalmology pipeline is becoming increasingly innovative, with a cluster of novel molecules in the early stages of development. There are currently five molecules in the pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicted for DES and three for glaucoma. Nearly 36% of the pipeline for glaucoma and DES consists of molecules in the late stages of development (Phases II and III), and of these, 21 molecules (43%) are indicated for DES and 28 (57%) for glaucoma. 

 Some of the major factors driving the growth of the market are the growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools, and an increase in the prevalence of both diseases. The expiration of blockbuster drug patents and the subsequent pressure from cheaper off-label products will be a key market restraint. A sizeable section of glaucoma patients require combination therapy – the use of additional agents to the treatment regimen – to control elevated intraocular pressure. The demand for combination products over single-ingredient formulations has risen, and they often improve patient compliance as the two drugs can be administered simultaneously. Diquas (diquafosol tetrasodium) by Santen Pharmaceutical and Mucosta (rebamipide) by Otsuka Holdings were both recently launched in Japan. These manufacturers must now focus on increasing diagnosis rates and growing their products’ market shares before looking at adding new therapies to the treatment scheme. In September 2008, Acucela and Otsuka signed an agreement to co-develop rebamipide ophthalmic suspension for DES in the US, where it is currently in Phase III trials. In addition to co-developing rebamipide ophthalmic suspension with Otsuka, Acucela will lead the regulatory process in submitting the drug for FDA approval. 

 Country  

 Global 

 Sector  

 Ophthalmology 

 1 Table of Contents 

 1.1 List of Tables 

 1.2 List of Figures 

 2 Ophthalmology Therapeutics in Major Markets - Introduction 

 2.1 Dry Eye Syndrome 

 2.1.1 Classification 

 2.1.2 Symptoms 

 2.1.3 Etiology 

 2.1.4 Pathophysiology 

 2.1.5 Diagnosis 

 2.1.6 Epidemiology 

 2.1.7 Prognosis 

 2.1.8 Treatment Options 

 2.2 Glaucoma 

 2.2.1 Classification 

 2.2.2 Symptoms 

 2.2.3 Etiology 

 2.2.4 Pathophysiology 

 2.2.5 Diagnosis 

 2.2.6 Epidemiology 

 2.2.7 Prognosis 

 2.2.8 Treatment Options 

 3 Ophthalmology Therapeutics in Major Markets - Marketed Products (Global) 

 3.1 Dry Eye Syndrome 

 3.2 Glaucoma 

 3.3 Key Marketed Products 

 3.3.1 Restasis 

 3.3.2 Systane 

 3.3.3 Diquas 

 3.3.4 Mucosta 

 3.3.5 Hyalein 

 3.3.6 Lumigan 

 3.3.7 Alphagan/Alphagan P 

 3.3.8 Simbrinza 

 4 Ophthalmology Therapeutics in Major Markets - Pipeline Analysis 

 4.1 Dry Eye Syndrome Pipeline 

 4.1.1 Overall Pipeline 

 4.1.2 Pipeline Analysis by Molecule Type 

 4.1.3 Pipeline Analysis by Mechanism of Action 

 4.2 Glaucoma Pipeline 

 4.2.1 Overall Pipeline 

 4.2.2 Pipeline Analysis by Molecule Type 

 4.2.3 Pipeline Analysis by Mechanism of Action 

 4.3 Promising Drug Candidates in the Pipeline 

 4.3.1 CF-101 

 4.3.2 MIM-D3 

 4.3.3 SAR-1118 

 4.3.4 DE-111 

 5 Ophthalmology Therapeutics in Major Markets - Market Forecast to 2019 

 5.1 Major Markets 

 5.1.1 Treatment Usage Patterns 

 5.1.2 Annual Cost of Therapy 

 5.1.3 Market Size 

 5.2 The US 

 5.2.1 Treatment Usage Patterns 

 5.2.2 Annual Cost of Therapy 

 5.2.3 Market Size 

 5.3 Top Five European Countries 

 5.3.1 Treatment Usage Patterns 

 5.3.2 Annual Cost of Therapy 

 5.3.3 Market Size 

 5.4 Canada 

 5.4.1 Treatment Usage Patterns 

 5.4.2 Annual Cost of Therapy 

 5.4.3 Market Size 

 5.5 Japan 

 5.5.1 Treatment Usage Patterns 

 5.5.2 Annual Cost of Therapy 

 5.5.3 Market Size 

 5.6 Drivers and Barriers 

 5.6.1 Drivers 

 5.6.2 Barriers 

 6 Ophthalmology Therapeutics in Major Markets - Deals and Strategic Consolidations (Global) 

 6.1 Deals Analysis 

 6.2 Major Co-Development Deals 

 6.2.1 NicOx Signs Research Agreement with Pfizer 

 6.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 

 6.2.3 Akorn Enters into Agreement with Azad Pharma 

 6.3 Major Licensing Deals 

 6.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 

 6.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 

 6.3.3 Asterand Enters into Licensing Agreement with Allergan 

 7 Ophthalmology Therapeutics in Major Markets - Appendix 

 7.1 All Pipeline Drugs by Phase 

 7.1.1 Discovery 

 7.1.2 Preclinical 

 7.1.3 IND/CTA-filed 

 7.1.4 Phase I 

 7.1.5 Phase II 

 7.1.6 Phase III 

 7.1.7 Pre-registration 

 7.1.8 Undisclosed 

 7.2 Market Forecasts to 2019 

 7.2.1 Major Markets 

 7.2.2 The US 

 7.2.3 The UK 

 7.2.4 France 

 7.2.5 Germany 

 7.2.6 Italy 

 7.2.7 Spain 

 7.2.8 Canada 

 7.2.9 Japan 

 7.3 Market Definitions 

 7.4 Abbreviations 

 7.5 Sources 

 7.6 Research Methodology 

 7.6.1 Coverage 

 7.6.2 Secondary Research 

 7.6.3 Primary Research 

 7.6.4 Therapeutic Landscape 

 7.6.5 Geographical Landscape 

 7.6.6 Pipeline Analysis 

 7.7 Expert Panel Validation 

 7.8 Contact Us 

 7.9 Disclaimer 

 1.1 List of Tables 

 Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 

 Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 

 Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 

 Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 

 Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 

 Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 

 Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 

 Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 

 Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 

 Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 

 Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 

 Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012-2019 

 Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012-2019 

 Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012-2019 

 Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012-2019 

 Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012-2019 

 Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012-2019 

 Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012-2019 

 Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012-2019 

 Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012-2019 

 Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012-2019 

 1.2 List of Figures 

 Figure 1: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006-2012 

 Figure 2: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010-2012 

 Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009-2012 

 Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009-2012 

 Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006-2012 

 Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006-2012 

 Figure 7: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 

 Figure 8: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 

 Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 

 Figure 10: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 

 Figure 11: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 

 Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 

 Figure 13: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012-2019 

 Figure 14: Ophthalmology Therapeutics Market, The US, Market Size, 2012-2019 

 Figure 15: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012-2019 

 Figure 16: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012-2019 

 Figure 17: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012-2019 

 Figure 18: Ophthalmology Therapeutics Market, Global, Deals, 2006-2013 

 Figure 19: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006-2013 

 Figure 20: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006-2013 

 Figure 21: GBI Research Market Forecasting Model